Amplification of tumor oxidative stresses with Shikonin-Fe(II) liposomal nanomedicine for enhanced anticancer treatment
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Bioactive Compounds and Antitumor Agents · Synthesis and Biological Evaluation · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (37)
Show source-provided references
1. Hu QL, Gao M, Feng GX, Liu B (2014) Mitochondria-targeted cancer therapy using a light-up probe with aggregation-induced-emission characteristics. Angew Chem Int Ed 53:14225–1422910.1002/anie.201408897 ↗
2. Dong ZL, Feng LZ, Chao Y, Hao Y, Chen MC, Gong F, Han X, Zhang R, Cheng L, Liu Z (2019) Amplification of tumor oxidative stresses with liposomal fenton catalyst and glutathione inhibitor for enhanced cancer chemotherapy and radiotherapy. Nano Lett 19:805–81510.1021/acs.nanolett.8b03905 ↗
3. Hou YK, Sun B, Li RT, Meng W, Zhang WH, Jia N, Chen M, Chen JX, Tang XY (2023) GSH-activatable camptothecin prodrug-loaded gold nanostars coated with hyaluronic acid for targeted breast cancer therapy via multiple radiosensitization strategies. J Mater Chem B 11:9894–991110.1039/D3TB00965C ↗
4. Moloney JN, Cotter TG (2018) ROS signalling in the biology of cancer. Semin Cell Dev Biol 80:50–6410.1016/j.semcdb.2017.05.023 ↗
5. Aboelella NS, Brandle C, Kim T, Ding ZC, Zhou G (2021) Oxidative stress in the tumor microenvironment and its relevance to cancer immunotherapy. Cancers (Basel) 13:98610.3390/cancers13050986 ↗
6. Lee SH, Gupta MK, Bang JB, Bae H, Sung HJ (2013) Current progress in reactive oxygen species (ROS)-responsive materials for biomedical applications. Adv Healthcare Mater 2:908–91510.1002/adhm.201200423 ↗
7. Wilson DS, Dalmasso G, Wang L, Sitaraman SV, Merlin D, Murthy N (2010) Orally delivered thioketal nanoparticles loaded with TNF-α-siRNA target inflammation and inhibit gene expression in the intestines. Nat Mater 9:923–92810.1038/nmat2859 ↗
8. Behrend L, Henderson G, Zwacka RM (2003) Reactive oxygen species in oncogenic transformation. Biochem Soc Trans 31:1441–144410.1042/bst0311441 ↗
9. Trachootham D, Alexandre J, Huang P (2009) Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discovery 8:579–59110.1038/nrd2803 ↗
10. Okon IS, Zou MHM (2015) Mitochondrial ROS and cancer drug resistance: implications for therapy. Pharmacol Res 100:170–17410.1016/j.phrs.2015.06.013 ↗
11. Nagano O, Okazaki S, Saya H (2013) Redox regulation in stem-like cancer cells by CD44 variant isoforms. Oncogene 32:5191–519810.1038/onc.2012.638 ↗
12. Matschke J, Riffkin H, Klein D, Handrick R, Lüdemann L, Metzen E, Shlomi T, Stuschke M, Jendrossek V (2016) Targeted inhibition of glutamine-dependent glutathione metabolism overcomes death resistance induced by chronic cycling hypoxia. Antioxid Redox Signaling 25:89–10710.1089/ars.2015.6589 ↗
13. Tiwari A, Trivedi R, Lin SY (2022) Tumor microenvironment: barrier or opportunity towards effective cancer therapy. J Biomed Sci 29:8310.1186/s12929-022-00866-3 ↗
14. Fang J, Seki T, Maeda H (2009) Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv Drug Delivery Rev 61:290–30210.1016/j.addr.2009.02.005 ↗
15. Tomasetti M, Santarelli L, Alleva R, Dong LF (2015) Redox-active and redox-silent compounds: synergistic therapeutics in cancer. J Neuzil Curr Med Chem 22:552–56810.2174/0929867321666140915142219 ↗
16. Kou LF, Sun R, Xiao SY, Zheng YW, Chen ZW, Cai AM, Zheng HL, Yao Q, Ganapathy V, Chen RJ (2019) Ambidextrous approach to disrupt redox balance in tumor cells with increased ROS production and decreased GSH synthesis for cancer therapy. ACS Appl Mater Interfaces 11:26722–2673010.1021/acsami.9b09784 ↗
17. Lennicke C, Rahn J, Lichtenfels R, Wessjohann LA, Seliger B (2015) Hydrogen peroxide- production, fate and role in redox signaling of tumor cells. Cell Commun Signaling 13:3910.1186/s12964-015-0118-6 ↗
18. Neyens E, Baeyens J (2003) A review of classic fenton’s peroxidation as an advanced oxidation technique. J Hazard Mater 98:33–5010.1016/S0304-3894(02)00282-0 ↗
19. Lin SH, Lo CC (1997) Fenton process for treatment of desizing wastewater. Water Res 31:2050–205610.1016/S0043-1354(97)00024-9 ↗
20. Guan Q, Zhou LL, Dong YB (2021) Ferroptosis in cancer therapeutics: a materials chemistry perspective. J Mater Chem B 9:8906–893610.1039/D1TB01654G ↗
21. Li YF, Wei C, Yan JQ, Li FS, Chen BH, Sun Y, Luo K, He B, Liang Y (2024) The application of nanoparticles based on ferroptosis in cancer therapy. J Mater Chem B 12:413–43510.1039/D3TB02308G ↗
22. Fei WD, Zhang Y, Ye YQ, Li CQ, Yao Y, Zhang M, Li FZ, Zheng CH (2020) Bioactive metal-containing nanomaterials for ferroptotic cancer therapy. J Mater Chem B 8:10461–1047310.1039/D0TB02138E ↗
23. Andújar I, Ríos JL, Giner RM, Recio MC (2013) Pharmacological properties of shikonin-a review of literature since 2002. Planta Med 79:1685–169710.1055/s-0033-1350934 ↗
24. Lin TJ, Lin HT, Chang WT, Mitapalli PS, Hsiao PW, Yin SY, Yang NS (2015) Shikonin-enhanced cell immunogenicity of tumor vaccine is mediated by the differential effects of DAMP components. Mol Cancer 14:17410.1186/s12943-015-0435-9 ↗
25. Vališ K, Talacko P, Grobárová V, Černý J, Novák P (2016) Shikonin regulates C-MYC and GLUT1 expression through the MST1-YAP1-TEAD1 axis. Exp Cell Res 349:273–28110.1016/j.yexcr.2016.10.018 ↗
26. Wang HR, Tang YS, Fang YF, Zhang M, Wang HY, He ZD, Wang B, Xu Q, Huang YZ (2019) Reprogramming tumor immune microenvironment (TIME) and metabolism via biomimetic targeting codelivery of shikonin/JQ1. Nano Lett 19:2935–294410.1021/acs.nanolett.9b00021 ↗
27. Lu B, Gong X, Wang ZQ, Ding Y, Wang C, Luo TF, Piao MH, Meng FK, Chi GF, Luo YN, Ge PF (2017) Shikonin induces glioma cell necroptosis in vitro by ROS overproduction and promoting RIP1/RIP3 necrosome formation. Acta Pharmacol Sin 38:1543–155310.1038/aps.2017.112 ↗
28. Guo CJ, He JL, Song XMT, Tan L, Wang M, Jiang PD, Li YZ, Cao ZX, Peng C (2019) Pharmacological properties and derivatives of shikonin-A review in recent year. Pharmacol Res 149:104463
29. Qian XY, Zhu L, Xu MZ, Liu HL, Yu XY, Shao QY, Qin J (2023) Shikonin suppresses small cell lung cancer growth via inducing ATF3-mediated ferroptosis to promote ROS accumulation. Chem Biol Interact 382:110588
30. Feng WJ, Shi WR, Cui YQ, Xu JJ, Liu SW, Gao H, Zhu SJ, Liu Y, Zhang H (2023) Fe(III)-Shikonin supramolecular nanomedicines as immunogenic cell death stimulants and multifunctional immunoadjuvants for tumor vaccination. Theranostics 13:5266–528910.7150/thno.81650 ↗
31. Liu ZD, Liu SN, Liu B, Bian YL, Yuan M, Yang CZ, Meng Q, Chen CX, Ma PA, Lin J (2023) Fe(III)-naphthazarin metal-phenolic networks for glutathione-depleting enhanced ferroptosis-apoptosis combined cancer therapy. Small 19:220782510.1002/smll.202207825 ↗
32. Dai YL, Yang Z, Cheng SY, Wang ZL, Zhang RL, Zhu GZ, Wang ZT, Yung BC, Tian R, Jacobson O, Xu C, Ni QQ, Song JB, Sun XL, Niu G, Chen XY (2018) Toxic reactive oxygen species enhanced synergistic combination therapy by self-assembled metal-phenolic network nanoparticles. Adv Mater 30:170487710.1002/adma.201704877 ↗
33. Sun Q, Gong T, Liu ML, Ren S, Yang H, Zeng S, Zhao H, Chen L, Ming TQ, Meng XL, Xu HB (2022) Shikonin, a naphthalene ingredient: therapeutic actions, pharmacokinetics, toxicology, clinical trials and pharmaceutical researches. Phytomedicine 94:153805
34. Feng WJ, Shi WR, Liu SW, Liu HW, Liu Y, Ge PF, Zhang H (2022) Fe(III)-shikonin supramolecular nanomedicine for combined therapy of tumor via ferroptosis and necroptosis. Adv Healthc Mate 11:210192610.1002/adhm.202101926 ↗
35. Feng LZ, Gao M, Tao DL, Chen Q, Wang HR, Dong ZL, Chen MW, Liu Z (2016) Cisplatin-prodrug-constructed liposomes as a versatile theranostic nanoplatform for bimodal imaging guided combination cancer therapy. Adv Funct Mater 26:2207–221710.1002/adfm.201504899 ↗
36. Yuba E (2020) Development of functional liposomes by modification of stimuli-responsive materials and their biomedical applications. J Mater Chem 8:1093–1107
37. Liu JJ, Yang GB, Zhu WW, Dong ZL, Yang Y, Chao YY, Liu Z (2017) Light-controlled drug release from singlet-oxygen sensitive nanoscale coordination polymers enabling cancer combination therapy. Biomaterials 146:40–4810.1016/j.biomaterials.2017.09.007 ↗